SEC Insider Transactions from Doyle Anthony.

Last updated: 2026-03-14 11:24 UTC | Total transactions: 9

Doyle Anthony has filed 9 insider transactions across 1 company since December 2023.

Most recent transaction: a grant/award of 120700 shares of BIOCRYST PHARMACEUTICALS INC ($BCRX) on December 19, 2024.

Activity breakdown: 1 open-market purchase and 0 sales.

Set Up your own filters →
Transaction Date Company Ticker Insider Name Title Transaction Type Security Shares Price Shares Owned Following Total Shares Outstanding % of Owned % of Outstanding
Dec. 19, 2024 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer A Common Stock 120700 $0.00 380,328.0000 206,905,000 46.49% 0.06%
Dec. 19, 2024 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer F Common Stock 2461 $7.39 377,867.0000 206,905,000 0.65% 0.00%
Dec. 19, 2024 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer A Emp. Stock Option (Right to Buy) 250100 $0.00 250,100.0000 206,905,000 9999.99% 0.12%
Dec. 14, 2024 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer F Common Stock 7890 $7.53 259,628.0000 206,905,000 2.95% 0.00%
May 14, 2024 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer P Common Stock 36300 $5.57 266,744.0000 192,198,000 15.75% 0.02%
Dec. 19, 2023 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer F Common Stock 2482 $6.05 227,444.0000 185,908,000 1.08% 0.00%
Dec. 14, 2023 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer A Common Stock 34000 $0.00 235,401.0000 185,908,000 16.88% 0.02%
Dec. 14, 2023 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer F Common Stock 5475 $6.43 229,926.0000 185,908,000 2.33% 0.00%
Dec. 14, 2023 BIOCRYST PHARMACEUTICALS INC $BCRX Doyle Anthony Chief Financial Officer A Emp. Stock Option (Right to Buy) 158500 $0.00 158,500.0000 185,908,000 9999.99% 0.09%